Patents by Inventor Lars Bärfacker
Lars Bärfacker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912692Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.Type: GrantFiled: August 11, 2023Date of Patent: February 27, 2024Assignee: Bayer AktiengesellschaftInventors: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Nils Pfaff, Stefanie Zimmermann, Markus Follmann, Elisabeth Kersten, Guillaume Levilain, Kartrin Partikel, Andreas Peter Broehl, Stefan Heitmeier, Julia Dietze-Torres, Lutz Lehmann, Kersten Matthias Gericke, Frank Süßmeier, Lars Bärfacker, Alexander Hillisch, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes
-
Publication number: 20230391761Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.Type: ApplicationFiled: August 11, 2023Publication date: December 7, 2023Inventors: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Nils Pfaff, Stefanie Zimmermann, Markus Follmann, Elisabeth Kersten, Guillaume Levilain, Kartrin Partikel, Andreas Peter Broehl, Stefan Heitmeier, Julia Dietze-Torres, Lutz Lehmann, Kersten Matthias Gericke, Frank Süßmeier, Lars Bärfacker, Alexander Hillisch, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes
-
Publication number: 20230226037Abstract: A compound represented by Formula (1) can be used as a prolonged ectoparasite-controlling agent for an animal. A preparation for systemic application for use in prolonged control of an ectoparasite in an animal include the compound. A method for prolonged control of an ectoparasite on an animal includes systemically applying the compound. The compound may be used for preparing a medicament for prolonged control of an ectoparasite on an animal. A horticultural or agricultural insecticide containing the compound, and a method of protecting a crop from a harmful organism is also provided.Type: ApplicationFiled: March 9, 2023Publication date: July 20, 2023Inventors: Yoji AOKI, Shinichi BANBA, Markus BERGER, Lars BAERFACKER
-
Patent number: 11696913Abstract: A compound represented by Formula (1) can be used as a prolonged ectoparasite-controlling agent for an animal. A preparation for systemic application for use in prolonged control of an ectoparasite in an animal include the compound. A method for prolonged control of an ectoparasite on an animal includes systemically applying the compound. The compound may be used for preparing a medicament for prolonged control of an ectoparasite on an animal. A horticultural or agricultural insecticide containing the compound, and a method of protecting a crop from a harmful organism is also provided.Type: GrantFiled: September 19, 2018Date of Patent: July 11, 2023Assignee: MITSUI CHEMICALS AGRO, INC.Inventors: Yoji Aoki, Shinichi Banba, Markus Berger, Lars Baerfacker
-
Publication number: 20230201174Abstract: The present invention relates to pharmaceutical compositions and combinations comprising finerenone or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and a SGLT2 inhibitor, or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof. The combination can be used for the treatment and/or prevention of cardiovascular and/or renal diseases in humans and other mammals.Type: ApplicationFiled: April 20, 2021Publication date: June 29, 2023Inventors: Peter KOLKHOF, Peter SANDNER, Lars BÄRFACKER
-
Publication number: 20200281914Abstract: A compound represented by Formula (1) can be used as a prolonged ectoparasite-controlling agent for an animal. A preparation for systemic application for use in prolonged control of an ectoparasite in an animal include the compound. A method for prolonged control of an ectoparasite on an animal includes systemically applying the compound. The compound may be used for preparing a medicament for prolonged control of an ectoparasite on an animal. A horticultural or agricultural insecticide containing the compound, and a method of protecting a crop from a harmful organism is also provided.Type: ApplicationFiled: September 19, 2018Publication date: September 10, 2020Inventors: Yoji AOKI, Shinichi BANBA, Markus BERGER, Lars BAERFACKER
-
Patent number: 10428044Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: June 17, 2015Date of Patent: October 1, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Keith Graham, Ulrich Klar, Hans Briem, Marion Hitchcock, Lars Bärfacker, Knut Eis, Volker Schulze, Gerhard Siemeister, Wilhelm Bone, Jens Schröder, Simon Holton, Philip Lienau, René Tempel, Helmut Sonnenschein, Jozsef Bálint, Heinz Graubaum
-
Patent number: 10370339Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: GrantFiled: June 3, 2016Date of Patent: August 6, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Sven Ring, Olaf Panknin, Katja Zimmermann, Judith Günther, Lars Bärfacker
-
Patent number: 10350206Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.Type: GrantFiled: September 17, 2015Date of Patent: July 16, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Anne Mengel, Hans-Georg Lerchen, Manfred Möwes, Thomas Müller, Lars Bärfacker, Marion Hitchcock, Arwed Cleve, Joachim Kuhnke, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Ursula Mönning, Simon Holton
-
Patent number: 10047096Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: November 23, 2015Date of Patent: August 14, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Schall, Jürgen Klar, Mario Lobell, Hartmut Schirok, Joachim Telser, Steffen Müller, Dirk Brohm, Hans Briem, Hannah Jörißen, Joerg Keldenich, Michael Böttger, Georges Von Degenfeld, Thomas Schlange, Ulf Bömer, Niels Lindner, Hanna Eilken, Dmitrij Hristodorov, Pierre Wasnaire, Kersten Matthias Gericke, Lars Bärfacker
-
Publication number: 20180170882Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 3, 2016Publication date: June 21, 2018Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Sven RING, Olaf PANKNIN, Katja ZIMMERMANN, Judith GÜNTHER, Lars BÄRFACKER
-
Publication number: 20170334899Abstract: The present invention relates to amino-substituted isothiazoles of general formula (I): in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 26, 2015Publication date: November 23, 2017Inventors: Lars BÄRFACKER, Gerhard SIEMEISTER, Tobias HEINRICH, Stefan PRECHTL, Detlef STÖCKIGT, Antje ROTTMANN
-
Publication number: 20170305882Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: October 26, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Hans-Georg LERCHEN, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNÁNDEZ-MONTÁLVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
-
Publication number: 20170275269Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
-
Publication number: 20170275270Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 15, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Lars BÄRFACKER, Thomas MÜLLER, Anne MENGEL, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
-
Publication number: 20170273980Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Hans-Georg LERCHEN, Manfred MÖWES, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Joachim KUHNKE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
-
Publication number: 20170275268Abstract: Compounds of formula (I), which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: March 10, 2017Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Marion HITCHCOCK, Anne MENGEL, Christoph-Stephan HILGER, Lars BÄRFACKER, Hans BRIEM, Gerhard SIEMEISTER, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Simon HOLTON, Cornelia PREUßE, Ursula MÖNNING
-
Publication number: 20170253602Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: November 23, 2015Publication date: September 7, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Andreas SCHALL, Jürgen KLAR, Mario LOBELL, Hartmut SCHIROK, Joachim TELSER, Steffen MÜLLER, Dirk BROHM, Hans BRIEM, Hannah JÖRIßEN, Joerg KELDENICH (deceased), Michael BÖTTGER, Georges DEGENFELD VON, Thomas SCHLANGE, Ulf BÖMER, Niels LINDNER, Hanna EILKEN, Dmitrij HRISTODOROV, Pierre WASNAIRE, Kersten Matthias GERICKE, Lars BÄRFACKER
-
Patent number: 9745285Abstract: Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: June 17, 2014Date of Patent: August 29, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Anne Mengel, Marion Hitchcock, Anja Richter, Lars Bärfacker, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Simon Holton, Cornelia Preuβe, Ursula Mönning
-
Publication number: 20170217946Abstract: The present invention relates to amino-substituted isoxazoles of general formula (I): in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 22, 2015Publication date: August 3, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Lars BÄRFACKER, Tobias HEINRICH, Gerhard SIEMEISTER, Stefan PRECHTL, Detlef STÖCKIGT, Antje ROTTMANN